176 related articles for article (PubMed ID: 37377894)
1. Targeting CHAF1B Enhances IFN Activity against Myeloproliferative Neoplasm Cells.
Saleiro D; Kosciuczuk EM; Fischietti M; Perez RE; Yang GS; Eckerdt F; Beauchamp EM; Hou Y; Wang Q; Weinberg RS; Fish EN; Yue F; Hoffman R; Platanias LC
Cancer Res Commun; 2023 May; 3(5):943-951. PubMed ID: 37377894
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.
Saleiro D; Wen JQ; Kosciuczuk EM; Eckerdt F; Beauchamp EM; Oku CV; Blyth GT; Fischietti M; Ilut L; Colamonici M; Palivos W; Atsaves PA; Tan D; Kocherginsky M; Weinberg RS; Fish EN; Crispino JD; Hoffman R; Platanias LC
Nat Commun; 2022 Apr; 13(1):1750. PubMed ID: 35365653
[TBL] [Abstract][Full Text] [Related]
3. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
[TBL] [Abstract][Full Text] [Related]
4. Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors.
Mehrotra S; Sharma B; Joshi S; Kroczynska B; Majchrzak B; Stein BL; McMahon B; Altman JK; Licht JD; Baker DP; Eklund EA; Wickrema A; Verma A; Fish EN; Platanias LC
J Biol Chem; 2013 Aug; 288(33):23814-22. PubMed ID: 23814052
[TBL] [Abstract][Full Text] [Related]
5. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Dagher T; Maslah N; Edmond V; Cassinat B; Vainchenker W; Giraudier S; Pasquier F; Verger E; Niwa-Kawakita M; Lallemand-Breitenbach V; Plo I; Kiladjian JJ; Villeval JL; de Thé H
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33075130
[TBL] [Abstract][Full Text] [Related]
6. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
7. CHAF1B induces radioresistance by promoting DNA damage repair in nasopharyngeal carcinoma.
Di M; Wang M; Miao J; Chen B; Huang H; Lin C; Jian Y; Li Y; Ouyang Y; Chen X; Wang L; Zhao C
Biomed Pharmacother; 2020 Mar; 123():109748. PubMed ID: 31869663
[TBL] [Abstract][Full Text] [Related]
8. CHAF1b, chromatin assembly factor-1 subunit b, is essential for mouse preimplantation embryos.
Zhang Y; Yang Y; Qiao P; Wang X; Yu R; Sun H; Xing X; Zhang Y; Su J
Int J Biol Macromol; 2022 Jan; 195():547-557. PubMed ID: 34906611
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J
Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
[TBL] [Abstract][Full Text] [Related]
10. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
Stein BL; Tiu RV
J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
[TBL] [Abstract][Full Text] [Related]
11. CHAF1B promotes proliferation and reduces apoptosis in 95‑D lung cancer cells and predicts a poor prognosis in non‑small cell lung cancer.
Duan Y; Liu T; Li S; Huang M; Li X; Zhao H; Li J
Oncol Rep; 2019 Apr; 41(4):2518-2528. PubMed ID: 30720130
[TBL] [Abstract][Full Text] [Related]
12. [Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].
Fu J; Xu Q; Zhao Y; Liu G; Cheng Z; Liang W; Xie X; Gu L
Zhonghua Yi Xue Za Zhi; 2015 Dec; 95(46):3727-32. PubMed ID: 26850010
[TBL] [Abstract][Full Text] [Related]
13. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Mosca M; Hermange G; Tisserand A; Noble R; Marzac C; Marty C; Le Sueur C; Campario H; Vertenoeil G; El-Khoury M; Catelain C; Rameau P; Gella C; Lenglet J; Casadevall N; Favier R; Solary E; Cassinat B; Kiladjian JJ; Constantinescu SN; Pasquier F; Hochberg ME; Raslova H; Villeval JL; Girodon F; Vainchenker W; Cournède PH; Plo I
Blood; 2021 Dec; 138(22):2231-2243. PubMed ID: 34407546
[TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.
Kiladjian JJ; Giraudier S; Cassinat B
Leukemia; 2016 Apr; 30(4):776-81. PubMed ID: 26601783
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
16. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
[TBL] [Abstract][Full Text] [Related]
17. The role of the chromatin assembly complex (CAF-1) and its p60 subunit (CHAF1b) in homeostasis and disease.
Volk A; Crispino JD
Biochim Biophys Acta; 2015 Aug; 1849(8):979-86. PubMed ID: 26066981
[TBL] [Abstract][Full Text] [Related]
18. Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms.
Hermange G; Cournède PH; Plo I
J Pharmacol Exp Ther; 2023 Oct; 387(1):31-43. PubMed ID: 37391225
[TBL] [Abstract][Full Text] [Related]
19. The histone H3/H4 chaperone CHAF1B prevents the mislocalization of CENP-A for chromosomal stability.
Shrestha RL; Balachandra V; Kim JH; Rossi A; Vadlamani P; Sethi SC; Ozbun L; Lin S; Cheng KC; Chari R; Karpova TS; Pegoraro G; Foltz DR; Caplen NJ; Basrai MA
J Cell Sci; 2023 May; 136(10):. PubMed ID: 37129573
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
